Detalle Publicación

ARTÍCULO
Plasma Aß42/40 ratio detects early stages of Alzheimer's disease and correlates with CSF and neuroimaging biomarkers in the AB255 study
Autores: Perez-Grijalba, V.; Romero, J. ; Pesini, P. (Autor de correspondencia); Sarasa, L.; Monleon, I.; San-Jose, I. ; Arbizu Lostao, Javier; Martinez-Lage, P. ; Munuera, J.; Ruiz, A.; Tarraga, L.; Boada, M.; Sarasa, M.; The AB255 Study Group
Título de la revista: JPAD
ISSN: 2274-5807
Volumen: 6
Número: 1
Páginas: 34 - 41
Fecha de publicación: 2019
Lugar: WOS
Resumen:
BACKGROUND: Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies. OBJECTIVES: This study evaluated the potential of plasma beta-amyloid (A beta) biomarkers in identifying early stages of AD and predicting cognitive decline over the following two years. DESIGN: Total plasma A beta 42/40 ratio (TP42/40) was determined in 83 cognitively normal individuals (CN) and 145 subjects with amnestic mild cognitive impairment (a-MCI) stratified by an FDG-PET AD-risk pattern. RESULTS: Significant lower TP42/40 ratio was found in a-MCI patients compared to CN. Moreover, a-MCIs with a high-risk FDG-PET pattern for AD showed even lower plasma ratio levels. Low TP42/40 at baseline increased the risk of progression to dementia by 70%. Furthermore, TP42/40 was inversely associated with neocortical amyloid deposition (measured with PiB-PET) and was concordant with the AD biomarker profile in cerebrospinal fluid (CSF). CONCLUSIONS: TP42/40 demonstrated value in the identification of individuals suffering a-MCI, in the prediction of progression to dementia, and in the detection of underlying AD pathology revealed by FDG-PET, Amyloid-PET and CSF biomarkers, being, thus, consistently associated with all the well-established indicators of AD.